Western Equine Encephalitis - Pipeline Review, H1 2020
![](/report_cover/2671/western-equine-encephalitis-pipeline-review-h1-2015_en.gif)
Western Equine Encephalitis - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Western Equine Encephalitis - Pipeline Review, H1 2020, provides an overview of the Western Equine Encephalitis (Infectious Disease) pipeline landscape.
Western equine encephalitis is a disease that is spread to humans by infected mosquitoes. Western equine encephalitis is caused by the western equine encephalitis virus, an arbovirus. Symptoms range from mild to severe and may include only fever and headache to encephalitis with delirium, disorientation or coma.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Western Equine Encephalitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Western Equine Encephalitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Western Equine Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Western Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively.
Western Equine Encephalitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Western Equine Encephalitis - Pipeline Review, H1 2020, provides an overview of the Western Equine Encephalitis (Infectious Disease) pipeline landscape.
Western equine encephalitis is a disease that is spread to humans by infected mosquitoes. Western equine encephalitis is caused by the western equine encephalitis virus, an arbovirus. Symptoms range from mild to severe and may include only fever and headache to encephalitis with delirium, disorientation or coma.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Western Equine Encephalitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Western Equine Encephalitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Western Equine Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Western Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively.
Western Equine Encephalitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Western Equine Encephalitis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Western Equine Encephalitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Western Equine Encephalitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Western Equine Encephalitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Western Equine Encephalitis (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Western Equine Encephalitis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Western Equine Encephalitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Western Equine Encephalitis - Overview
Western Equine Encephalitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Western Equine Encephalitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Western Equine Encephalitis - Companies Involved in Therapeutics Development
Akshaya Bio Inc
Bavarian Nordic A/S
Profectus BioSciences Inc
Western Equine Encephalitis - Drug Profiles
encephalitis (trivalent,virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
equine encephalitis (trivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
equine encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Myd88 for Infectious Diseases, Inflammation, Septic Shock and Toxic Shock - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Western Equine Encephalitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Western Equine Encephalitis Virus Vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Western Equine Encephalitis - Dormant Projects
Western Equine Encephalitis - Product Development Milestones
Featured News & Press Releases
Jan 24, 2019: Bavarian Nordic advances development of equine encephalitis virus vaccine
Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Western Equine Encephalitis - Overview
Western Equine Encephalitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Western Equine Encephalitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Western Equine Encephalitis - Companies Involved in Therapeutics Development
Akshaya Bio Inc
Bavarian Nordic A/S
Profectus BioSciences Inc
Western Equine Encephalitis - Drug Profiles
encephalitis (trivalent,virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
equine encephalitis (trivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
equine encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Myd88 for Infectious Diseases, Inflammation, Septic Shock and Toxic Shock - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Western Equine Encephalitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Western Equine Encephalitis Virus Vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Western Equine Encephalitis - Dormant Projects
Western Equine Encephalitis - Product Development Milestones
Featured News & Press Releases
Jan 24, 2019: Bavarian Nordic advances development of equine encephalitis virus vaccine
Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Western Equine Encephalitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Western Equine Encephalitis - Pipeline by Akshaya Bio Inc, H1 2020
Western Equine Encephalitis - Pipeline by Bavarian Nordic A/S, H1 2020
Western Equine Encephalitis - Pipeline by Profectus BioSciences Inc, H1 2020
Western Equine Encephalitis - Dormant Projects, H1 2020
Number of Products under Development for Western Equine Encephalitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Western Equine Encephalitis - Pipeline by Akshaya Bio Inc, H1 2020
Western Equine Encephalitis - Pipeline by Bavarian Nordic A/S, H1 2020
Western Equine Encephalitis - Pipeline by Profectus BioSciences Inc, H1 2020
Western Equine Encephalitis - Dormant Projects, H1 2020
LIST OF FIGURES
Number of Products under Development for Western Equine Encephalitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
Akshaya Bio Inc
Bavarian Nordic A/S
Profectus BioSciences Inc
Number of Products under Development for Western Equine Encephalitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
Akshaya Bio Inc
Bavarian Nordic A/S
Profectus BioSciences Inc